Cutler Group LP Actinium Pharmaceuticals, Inc. Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	BUY	$8.51 - $14.26 $14,109 - $23,643	1,658 Added 69.08%	4,058 $38,000
Q4 2022 Feb 07, 2023	SELL	$7.05 - $14.41 $5,068 - $10,360	-719 Reduced 23.05%	2,400 $25,000
Q3 2022 Oct 25, 2022	BUY	$4.81 - $8.48 $1,534 - $2,705	319 Added 11.39%	3,119 $23,000
Q2 2022 Aug 04, 2022	BUY	$4.71 - $7.11 $8,478 - $12,798	1,800 Added 180.0%	2,800 $13,000
Q1 2022 Apr 14, 2022	BUY	$4.57 - $6.4 $4,570 - $6,400	1,000 New	1,000 $5,000

7.05M

96.6K

70.5K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $47.3M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.